Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

Cantor starts Mereo BioPharma at OW; PT $4

Cantor Fitzgerald initiated coverage of Mereo BioPharma (NASDAQ:MREO) with an “overweight” rating and $4 price target. The stock closed at $1.15 on Aug. 11. Mereo is a clinical-stage biopharmaceutical company that is...

August 12, 2022

Markets

BTIG cuts Pear Therapeutics PT to $5 on Q2 results

BTIG reduced its price target for Pear Therapeutics (NASDAQ:PEAR) to $5 from $11 but maintained its “buy” rating after the company missed second quarter revenue consensus and lowered 2022 revenue guidance. The stock...

August 12, 2022

Markets

Cantor cuts TerrAscend to neutral on model update post Q2 miss

Cantor Fitzgerald downgraded TerrAscend (OTCQX:TRSSF) to “neutral” from “overweight” and reduced its price target to $2.85 from $6.45 on lower estimates and sectoral derating. The stock closed at $2.40 on Aug. 11...

August 12, 2022

Markets

SVB cuts 4D Molecular to MP on elevated risk to Fabry program

SVB Securities downgraded 4D Molecular Therapeutics (NASDAQ:FDMT) to “market perform” from “outperform” and reduced its price target to $12, citing an elevated risk to the lead Fabry disease program, along with an...

August 12, 2022

Markets

BTIG ups Acutus PT to $2.50 on Q2, strategy shift plan results

BTIG raised its price target for Acutus Medical (NASDAQ:AFIB) to $2.50 from $1.50 after the company beat consensus estimates for second quarter revenue. The stock closed at $1.66 on Aug. 11. Acutus Medical is a cardiac...

August 12, 2022

Developments

Rani Therapeutics posts positive Phase 1 results in osteoporosis

Rani Therapeutics (NASDAQ:RANI) reported positive topline results from the single-ascending dose portion of its Phase 1 clinical study of RT-102, a RaniPill capsule containing a proprietary formulation of human...

August 11, 2022

Markets

Cantor starts MindMed at OW; PT $3

Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...

August 10, 2022

Developments

SAB Biotherapeutics expanding pipeline for C. diff as DoD contract winds down

SAB Biotherapeutics (NASDAQ:SABS) will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019...

August 10, 2022

Developments

Blue Water Vaccines in $10-million private placement

Blue Water Vaccines (NASDAQ:BWV) entered into definitive agreements with several healthcare-focused institutional investors for the purchase of 3,683,280 common shares of the company in a private placement priced at-the...

August 9, 2022

Markets

Dawson James cuts Mesoblast to neutral on potential capital raise

Dawson James downgraded Mesoblast (NASDAQ:MESO; ASX:MSB) to “neutral” and removed its price target after the stock was halted on Aug. 4 in Australia with news of a proposed private placement and another notice of a halt...

August 8, 2022

Markets

Cantor cuts Galmed to neutral on limited insights into programs

Cantor Fitzgerald downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “neutral” from “overweight” and slashed its price target to 70 cents from $5 after the company announced a business update along with financials for...

August 4, 2022

Executive Moves

Enzo Biochem appoints Matthew Kupferberg as general counsel

Enzo Biochem (NYSE:ENZ) named Matthew Kupferberg as the company’s in-house general counsel. He was most recently general counsel, chief compliance officer and privacy officer of Digital Medical Technologies, a...

August 3, 2022

Cantor starts Mereo BioPharma at OW; PT $4

BTIG cuts Pear Therapeutics PT to $5 on Q2 results

Cantor cuts TerrAscend to neutral on model update post Q2 miss

SVB cuts 4D Molecular to MP on elevated risk to Fabry program

BTIG ups Acutus PT to $2.50 on Q2, strategy shift plan results

Rani Therapeutics posts positive Phase 1 results in osteoporosis

Cantor starts MindMed at OW; PT $3

SAB Biotherapeutics expanding pipeline for C. diff as DoD contract winds down

Blue Water Vaccines in $10-million private placement

Dawson James cuts Mesoblast to neutral on potential capital raise

Cantor cuts Galmed to neutral on limited insights into programs

Enzo Biochem appoints Matthew Kupferberg as general counsel

General

More